Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Hold at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

CMPX has been the topic of several other research reports. JMP Securities set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Citigroup assumed coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating for the company. Raymond James Financial restated an “outperform” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Tuesday, January 6th. Canaccord Genuity Group set a $13.00 target price on shares of Compass Therapeutics in a research note on Wednesday, February 4th. Finally, D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Compass Therapeutics Price Performance

CMPX stock opened at $6.28 on Monday. The stock has a market capitalization of $1.12 billion, a P/E ratio of -13.96 and a beta of 1.46. Compass Therapeutics has a 1-year low of $1.33 and a 1-year high of $6.88. The business has a fifty day moving average price of $5.67 and a 200-day moving average price of $4.51.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CMPX. LPL Financial LLC grew its position in shares of Compass Therapeutics by 4.7% during the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock valued at $239,000 after acquiring an additional 2,000 shares during the period. Victory Capital Management Inc. lifted its position in Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after purchasing an additional 2,164 shares in the last quarter. Focus Partners Wealth grew its holdings in Compass Therapeutics by 16.2% during the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after purchasing an additional 2,206 shares during the period. Dimensional Fund Advisors LP increased its position in Compass Therapeutics by 1.9% in the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after buying an additional 3,329 shares in the last quarter. Finally, Welch & Forbes LLC raised its stake in shares of Compass Therapeutics by 26.7% in the fourth quarter. Welch & Forbes LLC now owns 19,000 shares of the company’s stock worth $102,000 after buying an additional 4,000 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.